Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Malgorzata Trawinska"'
Autor:
Roberto Latagliata, Fabio Stagno, Mario Annunziata, Elisabetta Abruzzese, Alessandra Iurlo, Attilio Guarini, Carmen Fava, Antonella Gozzini, Massimiliano Bonifacio, Federica Sorà, Sabrina Leonetti Crescenzi, Monica Bocchia, Monica Crugnola, Fausto Castagnetti, Isabella Capodanno, Sara Galimberti, Costanzo Feo, Raffaele Porrini, Patrizia Pregno, Manuela Rizzo, Agostino Antolino, Endri Mauro, Nicola Sgherza, Luigiana Luciano, Mario Tiribelli, Antonella Russo Rossi, Malgorzata Trawinska, Paolo Vigneri, Massimo Breccia, Gianantonio Rosti, Giuliana Alimena
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 18, Iss 9, Pp 536-540 (2016)
Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we
Externí odkaz:
https://doaj.org/article/cf326cb4083d49d69854ac476b662cf8
Autor:
Sara Pepe, Elena Rossi, Malgorzata Trawinska, Caterina Tatarelli, Ambra Di Veroli, Luca Maurillo, Atelda Romano, Sabrina Leonetti Crescenzi, Tommaso Caravita di Toritto, Agostino Tafuri, Roberto Latagliata, Emilia Scalzulli, Alessandro Andriani, Valerio De Stefano, Massimo Breccia
Publikováno v:
Annals of Hematology. 101:1275-1282
Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study demonstrating the efficacy and safety of rux
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d1684178c8a95bbddc18767dce3e1b7
https://doi.org/10.1007/s00277-022-04815-w
https://doi.org/10.1007/s00277-022-04815-w